Science & Technology
STTR Phase I:Cardiotropic Atorvastatin Liposomes for Myocardial Reperfusion Injury
National Science Foundation
Opportunity #: 2300933
Award Ceiling
$275K
Award Floor
$275K
Close Date
Apr 30, 2024
Total Funding
$275K
Expected Awards
1
Posted Date
May 15, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-2300933
Description
STTR Phase Phase I award: "STTR Phase I:Cardiotropic Atorvastatin Liposomes for Myocardial Reperfusion Injury" awarded to HEXAKIT INC in EDMOND, Oklahoma. Funded by National Science Foundation. Award amount: $275,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.